WEBSITE CREATED IN

ADIPONRF2

Targeting the Keap1/Nrf2 pathway in adipose tissue for obesity prevention and treatment.

Περιγραφή εικόνας

This research addresses the question of how the manipulation of Keap1/Nrf2 signalling in adipose tissue affects the development of obesity and metabolic syndrome. Nrf2 is a central orchestrator of a battery of antioxidant and cytoprotective genes in response to oxidative or electrophilic stress and there is growing evidence that it cross-talks with other pathways. Our previous works showed that the whole body deletion of Nrf2 protected, at least partially, mice from high-fat diet (HFD)-induced obesity and insulin resistance and led to impaired adipogenesis. Another study has shown that mice treated with an Nrf2 activator, the triterpenoid CDDO-Im, were also protected from HFD-induced obesity. However, little is known about the exact mechanisms involved and which tissue is the main contributor to the resulting phenotype. Taking into account that there is in vitro evidence that Nrf2 is implicated in adipogenesis by crosstalking with transcription factors central to the adipocyte differentiation (PPARgamma, C/EBP beta), the main focus of this research will be to develop a murine model with conditional deletion of Nrf2 (loss of Nrf2 function) or Keap1 (gain of Nrf2 function) in adipose tissue using the Cre-recombinase-loxP system. Using both these models we will study how genetic manipulation of Nrf2 specifically in adipose tissue affects the development of HFD-induced obesity, the oxygen and energy consumption, the insulin resistance and the expression of genes involved in adipogenesis and lipid metabolism in adipose and other tissues in the different genotypes. Experiments using primary adipocyte cultures will give a mechanistic insight into adipogenesis and insulin signalling. This work will advance the field of obesity by actually being the first work that scrutinously characterize Nrf2 as a novel target for obesity prevention and treatment and possibly pave the way for relevant future clinical trials using Keap1/Nrf2 pathway modifying agents.

CORDIS WEBSITE http://cordis.europa.eu/project/rcn/107933_en.html

This website refers to the FP7-PEOPLE-2012-IOF -329442 Marie Curie Action: "International Outgoing Fellowships for Career Development". It is funded by the European Commission, Research Executive Agency.

 

The project is coordinated by the University of Patras, Greece. 


The outgoing phase is implemented by Dionysios Chartoumpekis MD, PhD in University of Pittsburgh in the School of Medicine, Department of Pharmacology & Chemical Biology. Outgoing scientist in charge: Professor Thomas W Kensler.

The reintegration phase will be implemented by Dionysios Chartoumpekis MD, PhD in the University of Patras, Department of Internal Medicine, Division of Endocrinology. Scientist in charge:  Associate Professor Ioannis Habeos.

Περιγραφή εικόνας